0216/26SCR018-12/R4RGB
Media Highlights
From the 2025 ASH Annual Meeting
4
Media Outlet Article / Coverage
ASH Clinical News
Beyond Disease Control: Person-Centered Care Advances Quality of
Life in Patients with Hemoglobinopathies
Barron's
Vertex Presents New Data on CASGEVY(R), Including First-
Ever Data in Children Ages 5-11 Years, at the American Society
of Hematology Annual Meeting and Announces Plan for Global
Regulatory Submissions
BioPharma Dive
Vertex CRISPR Therapy Hits Early Goal in Children with Blood Disorders
BioWorld
Casgevy for Kids? Expanding, Improving SCD Gene Therapies
Healio
'Extremely Encouraging': Exa-cel Benefits kids with Sickle Cell
Disease, Beta Thalassemia
Managed Healthcare Executive
Positive Results for Casgevy but with One Patient Death from
Myeloablative Busulfan Conditioning | ASH 2025
Medical X Press
Exa-cel Gene Therapy May Off Effective Cure for Beta-thalassemia
and Sickle Cell Disease in Children Younger than 12
MedPage Today
Gene Therapy Also Effective in Younger Children With Inherited
Blood Disorders
Medscape
Gene Therapy for SCD, TDT Promising in Younger Kids, Too
New England Journal of Medicine
Prime Editing for p47
phox
-Deficient Chronic Granulomatous Disease
News Medical Life Sciences
Exa-cel Shows Complete Success in Early Pediatric Trials for Sickle
Cell Disease and Beta-Thalassemia
Oncology News Central
Progress Amid Ongoing Pain: ASH 2025 Studies Show Mixed
Results in Sickle Cell Disease
Precision Medicine Online
Vertex Will Seek Regulatory Approval for Casgevy in Younger Sickle
Cell, Beta-Thalassemia Patients
STAT
'Remarkable' Drug Results Against an Aggressive Leukemia
The Pharma Letter
Vertex Presents New Data on CASGEVY at ASH
VJHemOnc
ASH 2025 | First Promising Results of Exa-Cel in Pediatric Patients
With TDT or SCD and Recurrent Severe VOCs
VJHemOnc
ASH 2025 | Fixed-dose vs Weight-based Plerixafor in Patients With
SCD Receiving BEAM-101 in the BEACON Trial
VuMedi
ASH 2025 Insights: First Results of Exagamglogene Autotemcel
in Pediatric Patients Aged 5-11 Years With Transfusion-Dependent
β-Thalassemia or Sickle Cell Disease With Recurrent Severe Vaso-
Occlusive Crises
VuMedi
ASH 2025 Insights: Fixed-Dose vs. Weight-Based Plerixafor Dosing
in Patients With Sickle Cell Disease Receiving Autologous CD34+
Base-Edited Hematopoietic Stem Cells (BEACON Study)
Haydar Frangoul, MD, MS
SCRI at TriStar Centennial Children's Hospital
